ResMed could regain its upward trend after having run out of steam.
According to Surperformance ratings, the group has strong fundamentals,as shown by the business predictability. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of USD 2.19 per share for the current year.
ResMed is in an uptrend in the medium and long term, but the last bearish movement returns close to a major support level (USD 42.8), level corresponding to the 20-week moving average. This threshold, if preserved, will enable to enjoy the bullish movement towards the USD 48.4 resistance.
It seems opportune to take a long position around the USD 42.8 support area with in line of sight the USD 48.4 resistance. A stop loss must be placed under the USD 42.8 support.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.
Designs, manufactures and markets devices for evaluation and treatment of sleep disordersResMed, Inc. engages in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep...